Our portfolio
One integrated platform for human-relevant drug discovery – from cells to clinical translation
myriamed connects the full iPSC-based drug discovery pipeline, from patient-derived cells and CRISPR-engineered disease models, through advanced reporter lines and 3D engineered tissues, to functional phenotypic screening and automated imaging. Built around our proprietary engineered tissue platforms, our products and services support pharmaceutical and biotech partners from early preclinical research through clinical translation, thus helping identify safer, more efficacious therapeutics with greater confidence and fewer integration gaps.
